pre-IPO PHARMA

COMPANY OVERVIEW

MiNA Therapeutics is pioneering novel treatments harnessing gene activation mechanisms through small activating RNA. saRNAs provide a new way of upregulating a cell’s messenger RNA (mRNA) and protein production. saRNA therapeutics hold promise for many conditions and diseases that are untreatable with conventional medicines.


LOCATION

  • London, , UK

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://minatx.com/


    CAREER WEBSITE

    https://minatx.com/careers_opportunities/


    SOCIAL MEDIA


    INVESTORS

    sosei


    PRESS RELEASES


    Apr 25, 2023

    MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases


    Apr 14, 2023

    MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting


    Apr 11, 2022

    MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy


    Dec 21, 2021

    MiNA Therapeutics Appoints Two Independent Directors With Extensive Industry Experience to Support Next Phase of Growth


    Dec 1, 2021

    National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer


    For More Press Releases


    Google Analytics Alternative